Vaxil Announces Positive Results on CorVax in vivo Study

NOT FOR DISTRIBUTION BY US NEWSWIRE OR IN UNITED STATES

NESS-ZIONA, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce that it has achieved positive results for the in vivo (animal) immunogenicity study which commenced on July 14, 2020.

The experiments, performed at the Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Sourasky Medical Center in Israel (the “Tel Aviv Sourasky Medical Centre”) were designed to evaluate, in vivo, the immune response to CorVax. The results successfully demonstrated both cellular and humoral responses to multiple signal peptides as well as to CorVax, composed of multiple signal peptides. These results further confirm the potential in the design of Vaxil’s COVID-19 vaccine candidate and provide additional evidence that it generates the anticipated immune response. A total of three injections were inoculated in two mouse strains to better simulate the human immune environment for which CorVax was specifically designed. Both mouse strains exhibited a humoral response, developing antibodies as early as 10 days after last injection. Both strains also displayed activated T cells against the signal peptides.

“We are delighted with these results, which indicate that further work is warranted to solidify the evidence behind the success of this study,” said Dr. David Hagin, Director of the Allergy and Clinical Immunology Unit at the Tel Aviv Medical Sourasky Center, and continued “from the outset, I was intrigued by Vaxil’s novel solution to a potential COVID-19 vaccine. We are seeing hundreds of patients at our hospital, daily, and therefore, to be involved in developing a potential solution to a global pandemic is particularly fulfilling.”

“We are very pleased with the outcome of this study, and will now weigh next steps to continue to produce more data, eventually to achieve approval to launch a clinical trial,” said David Goren, Vaxil’s Chairman and Chief Executive Officer, and continued, “our collaboration with Dr. Hagin and his team at the Tel Aviv Sourasky Medical Centre is extremely effective and I thank Dr. Hagin and his team for their outstanding commitment and professionalism.”